Please Wait
Applying Filters...
menu
    • menu
    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-03

    Virtual Booth

    An Enquiry

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Seralutinib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    $ API Ref.Price (USD/KG) : 93,099Xls

    Filters

    clear-filterReset all filters
    2D Structure
    Also known as: 1619931-27-9, Gb002, (s)-n-(3-(1-((6-(3,4-dimethoxyphenyl)pyrazin-2-yl)amino)ethyl)phenyl)-5-methylnicotinamide, Pk-10571, Seralutinib [usan], Gb-002
    Molecular Formula
    C27H27N5O3
    Molecular Weight
    469.5  g/mol
    InChI Key
    JHJNPOSPVGRIAN-SFHVURJKSA-N
    FDA UNII
    3P63ZTE3OY
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    N-[3-[(1S)-1-[[6-(3,4-dimethoxyphenyl)pyrazin-2-yl]amino]ethyl]phenyl]-5-methylpyridine-3-carboxamide
    2.1.2 InChI
    InChI=1S/C27H27N5O3/c1-17-10-21(14-28-13-17)27(33)31-22-7-5-6-19(11-22)18(2)30-26-16-29-15-23(32-26)20-8-9-24(34-3)25(12-20)35-4/h5-16,18H,1-4H3,(H,30,32)(H,31,33)/t18-/m0/s1
    2.1.3 InChI Key
    JHJNPOSPVGRIAN-SFHVURJKSA-N
    2.1.4 Canonical SMILES
    CC1=CC(=CN=C1)C(=O)NC2=CC=CC(=C2)C(C)NC3=NC(=CN=C3)C4=CC(=C(C=C4)OC)OC
    2.1.5 Isomeric SMILES
    CC1=CC(=CN=C1)C(=O)NC2=CC=CC(=C2)[C@H](C)NC3=NC(=CN=C3)C4=CC(=C(C=C4)OC)OC
    2.2 Other Identifiers
    2.2.1 UNII
    3P63ZTE3OY
    2.3 Synonyms
    2.3.1 Depositor-Supplied Synonyms

    1. 1619931-27-9

    2. Gb002

    3. (s)-n-(3-(1-((6-(3,4-dimethoxyphenyl)pyrazin-2-yl)amino)ethyl)phenyl)-5-methylnicotinamide

    4. Pk-10571

    5. Seralutinib [usan]

    6. Gb-002

    7. 3p63zte3oy

    8. N-[3-[(1s)-1-[[6-(3,4-dimethoxyphenyl)pyrazin-2-yl]amino]ethyl]phenyl]-5-methylpyridine-3-carboxamide

    9. 3-pyridinecarboxamide, N-(3-((1s)-1-((6-(3,4-dimethoxyphenyl)-2-pyrazinyl)amino)ethyl)phenyl)-5-methyl-

    10. Seralutinib [inn]

    11. Unii-3p63zte3oy

    12. Seralutinib [who-dd]

    13. Chembl4650333

    14. Schembl17324860

    15. Gtpl10618

    16. Ex-a5138

    17. Who 11243

    18. At11371

    19. Pk10571

    20. Structure 2a [wo2014110200a1]

    21. Hy-109190

    22. Cs-0116463

    23. N-(3-((1s)-1-((6-(3,4-dimethoxyphenyl)-2-pyrazinyl)amino)ethyl)phenyl)-5-methyl-3-pyridinecarboxamide

    2.4 Create Date
    2015-03-23
    3 Chemical and Physical Properties
    Molecular Weight 469.5 g/mol
    Molecular Formula C27H27N5O3
    XLogP33.7
    Hydrogen Bond Donor Count2
    Hydrogen Bond Acceptor Count7
    Rotatable Bond Count8
    Exact Mass469.21138974 g/mol
    Monoisotopic Mass469.21138974 g/mol
    Topological Polar Surface Area98.3 Ų
    Heavy Atom Count35
    Formal Charge0
    Complexity667
    Isotope Atom Count0
    Defined Atom Stereocenter Count1
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1